Erratum to: Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients

Marisa Iborra,Javier P. Gisbert,Marta Maia Bosca-Watts,Alicia López-García,Valle García-Sánchez,Antonio López-Sanromán,Esther Hinojosa,Lucía Marquez,Santiago García-López,María Chaparro,Montserrat Aceituno,M Calafat,Jordi Guardiola,Blanca Belloc,Yolanda Ber,Luis Bujanda,Belén Beltrán,Cristina Rodríguez Gutiérrez,Jesus Barrio,José Luis Cabriada,Montserrat Rivero,Raquel Camargo,Manuel Van Domselaar,A. Villoria,Hugo Salata Schuterman,David Hervás,Pilar Nos

Erratum to: Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients

2017

Background Ulcerative colitis (UC) treatment is focused to achieve mucosal healing, avoiding disease progression. The study aimed to evaluate the real-world effectiveness of adalimumab (ADA) in UC and to identify predictors of remission to ADA.

Keywords:

Ulcerative colitis
Clinical Practice
Necrosis
Disease
Diabetes mellitus
Physical therapy
Adalimumab
Medicine
Surgical oncology
General surgery
Hepatology
Colorectal surgery
Abdominal surgery
Internal medicine
Gastroenterology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations